LivaNova (NASDAQ:LIVN) Price Target Raised to $63.00

LivaNova (NASDAQ:LIVN) had its price objective upped by Robert W. Baird from $61.00 to $63.00 in a research report released on Thursday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

LIVN has been the subject of several other reports. Barclays raised their target price on shares of LivaNova from $55.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, August 21st. The Goldman Sachs Group set a $55.00 price target on shares of LivaNova and gave the company a “neutral” rating in a research report on Wednesday, October 1st. Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of LivaNova in a research report on Wednesday, October 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $64.00 target price on shares of LivaNova in a report on Wednesday, September 3rd. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $60.00.

LivaNova Stock Performance

Shares of NASDAQ LIVN opened at $50.45 on Thursday. The stock’s fifty day simple moving average is $54.02 and its 200 day simple moving average is $48.34. The stock has a market capitalization of $2.75 billion, a price-to-earnings ratio of -12.97 and a beta of 1.00. The company has a quick ratio of 1.09, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. LivaNova has a 52-week low of $32.48 and a 52-week high of $58.91.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, November 5th. The company reported $1.11 EPS for the quarter, beating the consensus estimate of $0.91 by $0.20. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The business had revenue of $357.80 million during the quarter, compared to the consensus estimate of $342.32 million. During the same period in the prior year, the business posted $0.90 earnings per share. LivaNova’s revenue was up 12.5% compared to the same quarter last year. LivaNova has set its FY 2025 guidance at 3.800-3.90 EPS. As a group, sell-side analysts forecast that LivaNova will post 2.85 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LivaNova

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its holdings in shares of LivaNova by 182.5% during the 2nd quarter. GAMMA Investing LLC now owns 630 shares of the company’s stock valued at $28,000 after acquiring an additional 407 shares in the last quarter. State of Wyoming purchased a new position in LivaNova in the second quarter valued at about $31,000. EverSource Wealth Advisors LLC increased its position in LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after purchasing an additional 639 shares during the last quarter. CWM LLC increased its position in LivaNova by 52.3% in the 1st quarter. CWM LLC now owns 871 shares of the company’s stock worth $34,000 after purchasing an additional 299 shares during the last quarter. Finally, UMB Bank n.a. raised its stake in shares of LivaNova by 63.0% during the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock worth $41,000 after purchasing an additional 306 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.